HIV

In a new commentary, scientists from the National Institutes of Health (NIH) assert that engaging men in HIV prevention and care is essential for ending the HIV pandemic.

A recent study compared the time to AIDS and mortality and the CD4 T-cell dynamics between HIV-1 and HIV-2, finding that both groups have a high probability of developing and dying from AIDS without antiretroviral treatment.

A new report from the CDC revealed that it is necessary for providers to be aware of the challenges faced by Hispanics/Latinos with diagnosed HIV and to improve access to ancillary services.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

As the world observes World AIDS Day 2018 on December 1, WalletHub has released an HIV/AIDS report in an effort to increase awareness about the virus.

This week, the top managed care news included a CMS plan for changes in drug coverage that brought a wave of criticism; a government task force recommended more people at risk for HIV take pre-exposure prophylaxis, known as PrEP; the American College of Cardiology issued an Expert Consensus Pathway on treatment of patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Here are the top 5 articles for the month of November.

The US Preventive Services Task Force (USPSTF) is recommending that clinicians offer the treatment to people at high risk of HIV, which will likely increase access to the treatment for those who need it most.

According to a new study, cellular proliferation generates the majority of infected cells during antiretroviral therapy (ART), suggesting that reducing proliferation can decrease the size of the HIV reservoir and work toward a cure.

Following release from prison or jail, people living with HIV have higher mortality rates than the general population, indicating that resources are needed to identify and treat HIV and other medical needs following release from incarceration in order to reduce mortality.

As physicians have an essential role in the fight against HIV—leading patients through the care continuum—understanding HIV-related stigma among physicians can inform development of interventions to reduce this stigma and promote positive clinical outcomes.

Family-centered pediatric advance care planning increased and maintained agreement about goals of care longitudinally, which lowered adolescents’ physical symptoms and suffering.

Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.

Recognizing a need for an outcome indicator for those newly diagnosed with HIV, researchers have proposed including the percentage of newly diagnosed persons achieving viral suppression within 3 months of diagnosis.

Building on positive 48-week data, Janssen released 96-week data demonstrating high rates of virogolic suppression and tolerability among antiretroviral therapy-naïve adults with HIV-1.

Following more than 1000 people living with HIV who were recently incarcerated, researchers observed that retention in care diminished significantly over time, but it was associated with HIV care during incarceration, health insurance, case management services, and early linkage to care post release.

According to a study presented at the ESMO 2018 Congress in Munich, Germany, treatment with PD-1 or PD-L1 inhibitors is a feasible option for patients who have cancer and are living with HIV.

Express Scripts' Aimee Tharaldson, PharmD, gave her overview of the specialty pharmacy pipeline for 2019 and beyond at the Academy of Managed Care Pharmacy Nexus 2018 meeting in Orlando, Florida.

A population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men resulted in a 25% reduction in HIV diagnoses in just 1 year.

The novel vaccine—eOD-GT8 60mer—stimulates the immune system to initiate a key first step in the generation of potent proteins, known as broadly neutralizing antibodies.

Today, HHS announced that approximately $2.34 billion in Ryan White HIV/AIDS Program grants were awarded to cities, counties, states, and local community-based organizations during fiscal year 2018.

Treatment with Symtuza (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) results in and maintains high virologic suppression rates, according to study findings presented at the 2018 Infectious Disease Week conference held in San Francisco, California.

Two studies presented at the 2018 Infectious Disease Week conference held in San Francisco, California, add to a pile of research demonstrating the positive impact of collaborative, multidisciplinary care in the HIV population, specifically on viral suppression.

A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.

Young men who have sex with men (MSM) who used the PrEPmate intervention were more likely to attend study visits and have higher rates of adherence to the prevention treatment.